PCN169 COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB FOR THE FIRST-LINE TREATMENT OF ADVANCED/METASTATIC RENAL CELL CARCINOMA IN GREECE
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.365
https://www.valueinhealthjournal.com/article/S1098-3015(19)32743-3/fulltext
Title :
PCN169 COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB FOR THE FIRST-LINE TREATMENT OF ADVANCED/METASTATIC RENAL CELL CARCINOMA IN GREECE
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32743-3&doi=10.1016/j.jval.2019.09.365
First page :
Section Title :
Open access? :
No
Section Order :
10300